Meta Pixel

News and Announcements

Exclusive BOND offering 8-18% brought to you by Kensington Capital and Cyferd

  • Published November 09, 2020 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

“As CEO of Cyferd, I have come off back to back exits, one in 2017, I then formed another tech company in 2018 which was acquired earlier this year. I currently run mergers and acquisitions for a $6BN company, this is my expertise and my skill set. In this round of funding Cyferd are looking to raise £1,800,000 to further develop the software and aid in building the best team possible.”

Ranjit Bahia, CEO, Cyferd

Register Interest

Problem

At the moment core systems are too slow to adapt to rapidly changing business environments. As demonstrated by the issues companies across the world suffered through the sudden threat and disruption caused by the Coronavirus.

Solution

The solution Cyferd are offering is a software that consolidates Low Code, IPA/RPA, Enterprise Integration Platforms and Locational Intelligence into one platform as a base for a more automated and informed process with AI and evolved learning at its core.

Competitive Edge

Cyferd’s competitive edge comes from the team behind the company, their track records and the value and networks they bring to the company. Cyferd’s vision to be the only choice for enterprises and governments as well as the fact the there is nothing currently out there like Cyferd.

Team Experience

The reason Cyferd is going to be such a big success is because of the team running it. The whole of Cyferd upper management have all come from billion $ companies and are market leaders at what they do.

Raise

Their offering is in two stages, the first £250,000 they are offering 18%. Once this round has passed the offering will be split into 3 brackets 8%, 10% and 12% depending on the level of investment.

Ambitions

Their vision is to become the leading digital transformation platform that allows enterprises and governments to become more automated and intelligent.

Highlights

  • Early adopters include the NHS, HSBC, Sony Playstation and Chubb Insurance
  • ISV alliances with Amazon, Google, Blackberry Cylance and Microsoft.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now